Compare Crispr Therapeutics AG (CRSP) vs Walt Disney Co (DIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Walt Disney Co — how do they compare? Crispr Therapeutics AG trades at $53.78 (market cap $5.22B), while Walt Disney Co trades at $104.46 (market cap $178.23B). The key difference: Walt Disney Co is far larger — about 34.1× Crispr Therapeutics AG's market cap, and Walt Disney Co pays a 1.45% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | DIS | |
|---|---|---|
Market Cap | $5.22B | $178.23B |
Sector | Health | Media |
52-Week High | $76.78 | $118.86 |
52-Week Low | $44.34 | $92.40 |
Enterprise Value | $3.64B | $219.08B |
Volume | — | 7,546,013 |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Walt Disney (DIS) trades at $103.51, up 0.31% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $94.43B in 2025 and net income surging to $12.40B. Recent earnings beats and a 62.5% analyst buy rating support positive sentiment, though RSI levels suggest potential overbought conditions. Disney faces regulatory challenges with the FCC while leveraging major advertising opportunities from upcoming Super Bowl and awards show broadcasts.
Disney presents a compelling investment case with solid earnings momentum and strategic positioning in streaming and theme parks. The consensus price target of $126 implies 22% upside potential. Key risks include regulatory pressures from FCC license reviews and box office performance concerns following Star Wars franchise challenges. Institutional confidence remains high with improving cash flow trends and debt reduction strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →
